Global meningitis vaccines market is estimated to be valued at USD 3.72 Bn in 2024, exhibiting a CAGR of 6.6% during the forecast period (2024-2031). Meningitis is a potentially fatal inflammation of the protective membranes covering the brain and spinal cord known as meninges. It can be caused by various pathogens such as bacteria, viruses, parasites, and fungi. The most common causes of meningitis are viral and bacterial infections. Bacterial infections including those caused by Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type b can rapidly lead to serious illness and even death if not treated promptly with appropriate antibiotics. While timely treatment with antibiotics can cure most cases of bacterial meningitis, the infection may still lead to long-term disability in 10-15% of cases such as hearing loss, neurodevelopmental delay, and epilepsy or limb amputations. To prevent the occurrence of invasive meningococcal disease caused by N. meningitidis, vaccination is recommended. Meningococcal conjugate vaccines have been created to provide both direct protection and herd immunity, effectively controlling the spread of the disease within communities.  

Market Dynamics

Global meningitis vaccines market growth is primarily driven by increasing burden of invasive meningococcal disease and implementation of large-scale immunization programs worldwide. For instance, as per the data published by the World Health Organization (WHO) in 2021, meningitis causes approximately 250,000–500,000 cases annually resulting in over 30,000 deaths, making it a public health priority. Evolving epidemiology of common pathogenic serogroups causing outbreaks, recommendations for routine immunization by national regulatory bodies and availability of vaccine combinations are expected to create robust growth opportunities in the market during the forecast period. However, factors such as high costs associated with the manufacturing and development of novel vaccines, vaccine stockouts during outbreaks, and lack of awareness in low and middle-income countries can hamper the market growth. Development of affordable multivalent vaccines covering emerging serotypes and expansion of immunization programs in developing nations present lucrative opportunities for player engagement and further market expansion.

Key Features of the Study

- This report provides in-depth analysis of the global meningitis vaccines market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year

- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

- It profiles key players in the global meningitis vaccines market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies

- Key companies covered as a part of this study include Pfizer Inc., Sanofi, GSK plc., Serum Institute of India Ltd., Merck & co., Inc., Walvax Biotechnology Co., Ltd., Icepta Pharmaceuticals Ltd., and Hualan Biological Engineering Inc.

- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

- Global meningitis vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Market Segmentation

•  Type Insights
• • Bivalent
  • Quadrivalent
  • Others
•  Brand Insights
• • MenQuadfi
  • Menveo
  • Trumenba
  • Bexsero
  • Others
•  Age Group Insights
• • Infants
  • Adults
•  Serotype Insights
• • Serotype A
  • Serotype B
  • Serotype C
  • Serotype W-135
  • Others
•  Sales Channel Insights
• • Private
  • Public
• Regional Insights
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Pfizer Inc.
  • Sanofi
  • GSK plc.
  • Serum Institute of India Ltd.
  • Merck & co., Inc.
  • Walvax Biotechnology Co., Ltd.
  • Icepta Pharmaceuticals Ltd.
  • Hualan Biological Engineering Inc.